Please Wait

Applying Filters...

Frimig
USDMF
Table View

AI drug discovery market to grow 30% CAGR, to reach US$ 35 bn by 2034; Novo, Lilly, BMS forge deals

Data Compilation
#PharmaFlow

Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

Stock Recap
#PipelineProspector

Frimig

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

51 API Suppliers, 26 USDMF, 14 CEP/COS, 4 JDMF, 13 EU WC, 6 KDMF, 20 NDC API, 26 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

6 Drugs in Development

6 Drugs in Development

INTERMEDIATES

5 Intermediate Suppliers

5 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

396 FDF Dossiers, 100 FDA Orange Book, 212 Europe, 34 Canada, 16 Australia, 19 South Africa, 15 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML), INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 100MG BASE, TABLET;ORAL - EQ 25MG BASE, TABLET;ORAL - EQ 50MG BASE, SYSTEM;IONTOPHORESIS - EQ 6.5MG BASE/4HR, POWDER;NASAL - EQ 11MG BASE, SPRAY;NASAL - 20MG/SPRAY, SPRAY;NASAL - 5MG/SPRAY, TABLET;ORAL - 500MG;EQ 85MG BASE, TABLET;ORAL - 60MG;EQ 10MG BASE, INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML), INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

RELATED EXCIPIENT COMPANIES

1 Actylis, 1 Finar

EXCIPIENTS BY APPLICATIONS

1 Parenteral, 1 Topical

DIGITAL CONTENT

35 News #PharmaBuzz

35 News #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 178 Regulatory FDF Prices, 8 Annual Reports

MARKET PLACE

11 APIs, 1 FDF Dossiers

PATENTS & EXCLUSIVITIES

49 US Patents, 10 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 3 USP, 5 Others

$ Xls download

Filters

Log in to access your PharmaMiles and download the data

Last Updated on PharmaCompass	Virtual Booth	Country	Holder	DMF No.	Subject	Submission Date	Status	Type	GDUFA DMF Review	GDUFA Review Date	GDUFA Payment Date
24/02/2025	Dr. Reddy\'s Laboratories	India	DR REDDYS LABORATORIES LTD	16534	SUMATRIPTAN SUCCINATE	2003-03-21	Active	II	N/A
24/02/2025	Moehs Iberica	Spain	MOEHS IBERICA SL	17352	SUMATRIPTAN SUCCINATE	2004-04-29	Active	II	Complete	2013-06-24	2013-06-19

Contact us
to update this info

Frimig

Frimig

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

51 API Suppliers

26 USDMF

14 CEP/COS

4 JDMF

13 EU WC

6 KDMF

20 NDC API

26 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

6 Drugs in Development

INTERMEDIATES

5 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

396 FDF Dossiers

100 FDA Orange Book

212 Europe

34 Canada

16 Australia

19 South Africa

15 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 100MG BASE

TABLET;ORAL - EQ 25MG BASE

TABLET;ORAL - EQ 50MG BASE

SYSTEM;IONTOPHORESIS - EQ 6.5MG BASE/4HR

POWDER;NASAL - EQ 11MG BASE

SPRAY;NASAL - 20MG/SPRAY

SPRAY;NASAL - 5MG/SPRAY

TABLET;ORAL - 500MG;EQ 85MG BASE

TABLET;ORAL - 60MG;EQ 10MG BASE

INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

RELATED EXCIPIENT COMPANIES

1 Actylis

1 Finar

EXCIPIENTS BY APPLICATIONS

1 Parenteral

1 Topical

DIGITAL CONTENT

35 News #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions

178 Regulatory FDF Prices

8 Annual Reports

MARKET PLACE

11 APIs

1 FDF Dossiers

PATENTS & EXCLUSIVITIES

49 US Patents

10 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM

3 USP

5 Others

Filters

INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons